Oncology Practice Management Issues


August 2013, Vol 3, No 5

Pharmacyclics Submits NDA for Ibrutinib

Clinical Trials Tracker

Pharmacyclics, a clinical-stage bio­­-pharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune-mediated diseases, has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the investigational oral Bruton’s [ Read More ]

Array BioPharma Initiates MILO Study

Clinical Trials Tracker

Array BioPharma said a $5-million milestone was achieved after the start of Array’s phase 3 trial in patients with low-grade serous ovarian cancer (LGSOC). The study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), is a multinational, randomized, [ Read More ]

FDA Approves 2 GSK Oral Oncology Treatments

Clinical Trials Tracker

GlaxoSmithKline (GSK), a re­search-based pharmaceutical and healthcare company, announced that the US Food and Drug Administration (FDA) has approved both Tafinlar (dabrafenib) and Mekinist (trametinib). Tafinlar is indicated as a single- agent oral treatment for unresectable melanoma (melanoma that cannot [ Read More ]

5 Common Estate-Planning Pitfalls and How to Avoid Them

Uncategorized

Estate planning is a process designed to help you manage and preserve your assets while you are alive, and to conserve and control their distribution after your death pursuant to your goals and objectives. This article will provide a brief [ Read More ]